Last reviewed · How we verify
Cotadutide 100 micrograms
Cotadutide is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glucose control and promote weight loss.
Cotadutide is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glucose control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or overweight with weight-related comorbidities.
At a glance
| Generic name | Cotadutide 100 micrograms |
|---|---|
| Also known as | MEDI0382 |
| Sponsor | AstraZeneca |
| Drug class | Dual GLP-1/glucagon receptor agonist |
| Target | GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR) |
| Modality | Small molecule |
| Therapeutic area | Diabetes, Obesity |
| Phase | Phase 2 |
Mechanism of action
By simultaneously activating GLP-1 and glucagon receptors, cotadutide enhances insulin secretion, reduces glucagon when appropriate, slows gastric emptying, and increases energy expenditure. This dual mechanism is designed to provide superior glycemic control and weight reduction compared to GLP-1 monotherapy, particularly in patients with type 2 diabetes and obesity.
Approved indications
- Type 2 diabetes mellitus
- Obesity or overweight with weight-related comorbidities
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cotadutide 100 micrograms CI brief — competitive landscape report
- Cotadutide 100 micrograms updates RSS · CI watch RSS
- AstraZeneca portfolio CI